Who Owns Treace Medical Concepts Company?

Treace Medical Concepts Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Treace Medical Concepts?

Understanding Treace Medical Concepts' ownership is key to its strategy and accountability in the medical tech sector. Its April 2021 IPO marked a significant shift from private to public ownership.

Founded by John T. Treace in 2013, the company focuses on surgical solutions for foot deformities, notably the Lapiplasty 3D Bunion Correction System. As of July 23, 2025, its market cap is around $383.41 million.

The ownership structure has evolved, with founders, key investors, and public shareholders all playing a role. This dynamic influences the company's direction in the competitive medical device industry.

Treace Medical Concepts, Inc. was established in July 2013 by John T. Treace, a seasoned professional with over 25 years in the medical device industry. His leadership has been instrumental in the company's growth and product development.

Founder's Vision John T. Treace founded the company with a clear objective to innovate in foot and ankle surgery. His vision led to the creation of the Lapiplasty system. Product Development In 2014, Mr. Treace collaborated with orthopedic surgeons to address critical issues in foot and ankle procedures. This collaboration resulted in the development of the Lapiplasty system. Leadership Role John T. Treace has consistently served as the Chief Executive Officer and a board member since the company's inception. His ongoing leadership is a key aspect of Treace Medical Concepts. Early Board Member James T. Treace played a significant role as Chairman of the Board from the company's founding in 2014 until his retirement in May 2025. His contributions were vital in the early stages. Founding Principles The company's foundation is built on a commitment to addressing the root causes of bunion deformities. This focus is evident in the design and purpose of the Lapiplasty system. Shareholder Information As of 2025, John T. Treace is the largest individual shareholder, holding 25.57 million shares, representing approximately 40.65% of the company's stock.

While the precise initial equity distribution is not publicly documented, the founder's significant stake underscores his foundational role and continued influence. The early strategic decisions, including the collaboration with surgeons to refine the Lapiplasty system, highlight a commitment to addressing specific market needs within the foot and ankle segment, a key aspect of the Target Market of Treace Medical Concepts.

Key Ownership Details

John T. Treace, the founder, remains the largest individual shareholder, holding a substantial portion of the company's stock as of 2025. This significant ownership reflects his integral role in the company's establishment and ongoing operations.

• Founder: John T. Treace
• Founding Year: 2013
• CEO and Board Member: John T. Treace
• Largest Individual Shareholder (as of 2025): John T. Treace
• John T. Treace's Shareholding (as of 2025): 25.57 million shares (approx. 40.65%)
• Former Chairman of the Board: James T. Treace (retired May 2025)

Treace Medical Concepts SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Treace Medical Concepts, Inc. became a publicly traded entity on April 23, 2021, through its Initial Public Offering on Nasdaq under the ticker 'TMCI'. This event marked a significant shift in its ownership structure, transitioning from private to public hands.

The ownership landscape of Treace Medical Concepts shows a substantial presence of institutional investors, holding approximately 60.61% of the company's shares as of July 22, 2025. This figure represents a notable increase from the 53% ownership recorded on June 18, 2025. Individual insiders collectively maintain a significant stake of 25.1%. The founder and CEO, John T. Treace, is the largest individual shareholder with 18.6% of the company's stock as of March 24, 2025. Other key institutional stakeholders as of March 31, 2025, include Armistice Capital LLC at 9.87%, BlackRock, Inc. at 6.15%, and William Blair Investment Management, LLC at 4.88%. Collectively, the top seven shareholders own 52% of the company, indicating a concentrated ownership among major players. These shifts and the significant institutional backing can influence the company's strategic direction and governance, reflecting the impact these large investors have on stock performance and corporate decisions. Understanding the Mission, Vision & Core Values of Treace Medical Concepts can provide further context to the company's strategic objectives and how stakeholders align with them.

Key Treace Medical Concepts Ownership Details

Institutional investors are the dominant shareholders in Treace Medical Concepts, holding over half of the company's stock.

• Institutional investors hold 60.61% as of July 22, 2025.
• Insider ownership stands at 25.1%.
• John T. Treace, CEO and Founder, is the largest individual shareholder with 18.6%.
• Major institutional investors include Armistice Capital LLC (9.87%) and BlackRock, Inc. (6.15%).
• The top 7 shareholders collectively own 52% of the company.

Treace Medical Concepts PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of July 2025, Treace Medical Concepts, Inc. is governed by a Board of Directors that includes its CEO, Founder, and Chairman of the Board, John T. Treace. The board comprises several other key individuals, including John K. Bakewell, Lance A. Berry, Lawrence W. Hamilton, Betsy Hanna, Deepti Jain, Jane E. Kiernan, and Richard W. Mott, who also serves as the lead independent director.

The company operates under a one-share-one-vote system for its common stock, meaning each share grants its holder a single vote on matters presented to stockholders, including director elections. There are no provisions for cumulative voting, which allows a majority of voting shares to elect all directors. Treace Medical Concepts has authorized 300 million shares of common stock and 5 million shares of preferred stock, though no preferred stock is currently outstanding. The board retains the authority to issue preferred stock with varied voting rights, but no such issuances are currently active that would alter the fundamental voting power distribution.

Board Leadership and Voting Power

The founder's influence remains significant in the company's governance. John T. Treace transitioned to Chairman of the Board following the 2025 annual meeting of stockholders, succeeding James T. Treace.

• John T. Treace holds key leadership positions as CEO, Founder, and Chairman.
• The voting structure is based on a one-share-one-vote principle.
• No cumulative voting rights exist for director elections.
• The company's governance is detailed in its amended and restated certificate of incorporation and bylaws.
• Understanding the Marketing Strategy of Treace Medical Concepts can provide context to the company's overall direction and stakeholder engagement.

Treace Medical Concepts Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, Treace Medical Concepts has seen significant shifts in its ownership. The company's initial public offering in April 2021 marked a turning point, leading to changes in its market capitalization and investor base. Understanding these trends is key to grasping the current Treace Medical Concepts ownership structure.

Institutional investors hold a substantial portion of Treace Medical Concepts, indicating a significant influence on stock performance. As of July 22, 2025, institutions owned approximately 60.61% of the company's shares, a slight increase from the 53% recorded on June 18, 2025. This high level of institutional Treace Medical Concepts investors suggests that their trading decisions can heavily impact the stock price. Meanwhile, individual insiders, including founder John T. Treace, collectively possess about 25.1% of the shares. Founder John T. Treace has demonstrated continued confidence through recent stock purchases, including a US$524,064 buy in March 2025 and earlier acquisitions in August and September 2024. Notably, there has been no insider selling observed over the past twelve months, highlighting a positive sentiment among key internal stakeholders.

Institutional Ownership Dominance

Institutions collectively own over 60% of Treace Medical Concepts as of July 2025. This concentration of ownership means institutional trading activity can significantly sway the company's stock price.

Insider Confidence and Investment

Founder John T. Treace and other insiders hold a considerable stake, with recent purchases signaling strong internal belief. The absence of insider selling over the last year further reinforces this positive outlook.

Product Portfolio Expansion

The company continues to grow its product offerings with recent limited market releases. Additional launches are anticipated throughout 2025, indicating a focus on innovation and market penetration.

Financial Performance and Guidance

Full-year 2024 revenue reached $209.4 million, a 12% increase from 2023. The company projects 2025 revenue between $224 million and $230 million, representing a 7% to 10% growth.

Despite positive product development and revenue growth, Treace Medical Concepts is currently facing a class-action lawsuit. Filed on April 11, 2025, the suit alleges that the company promoted its Lapiplasty system between May 8, 2023, and May 7, 2024, while failing to disclose critical risks. This alleged omission reportedly contributed to a significant 63% stock price decline following a revenue guidance cut on May 7, 2024. Shareholders who held their positions prior to May 8, 2023, are being advised to explore options for corporate reform. This situation highlights the complexities that can arise in the Competitors Landscape of Treace Medical Concepts, impacting Treace Medical Concepts stakeholders.

Treace Medical Concepts Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔